Skip to main content
Explore URMC
URMC / Research / Clinical Trials / Study Details

IHEM17093 / PAC203 / Jane Liesveld

Research Question:
What dose of the study drug, pacritinib, is safest and works best for patients with myelofibrosis?

Basic Study Information

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or to P/C therapy (approximately 116 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib

Location: Cancer Center
Study Web URL:
Study Reference #: IHEM17093

Lead Researcher (Principal Investigator)

Lead Researcher:  Jane Liesveld, MD

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475

Additional Study Details

Parking:  Reimbursed

Learn More About These Conditions

More information about Myelofibrosis

Return to Search